Based on the Amedisys Inc stock forecast from 2 analysts, the average analyst target price for Amedisys Inc is USD 101.00 over the next 12 months. Amedisys Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Amedisys Inc is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, Amedisys Inc’s stock price was USD 90.64. Amedisys Inc’s stock price has changed by +0.66% over the past week, -6.89% over the past month and -3.32% over the last year.
No recent analyst target price found for Amedisys Inc
No recent average analyst rating found for Amedisys Inc
Company Overview Amedisys Inc
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana. Address: 3854 American Way, Baton Rouge, LA, United States, 70816 Read Less
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of pa...Read More
Frequently Asked Questions About Amedisys Inc (AMED) Stock
Based on ratings from 2 analysts Amedisys Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on AMED's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for AMED is USD 101.00 over the next 12 months. The maximum analyst target price is USD 101 while the minimum anlayst target price is USD 101.
AMED stock's Price/Earning ratio is 35.97.
Our analysis grades AMED stock's Price / Earning ratio at F. This means that AMED stock's Price/Earning ratio is above 56.00000000000001% of the stocks in the Medical Care Facilities sector in the NSD exchange.
Based on this AMED may be a overvalued for its sector.
The last closing price of AMED's stock was USD 90.64.
The most recent market capitalization for AMED is USD 2.97B.
Based on targets from 2 analysts, the average taret price for AMED is projected at USD 101.00 over the next 12 months.
This means that AMED's stock price may go up by +11.43% over the next 12 months.
We can't find any ETFs which contains Amedisys Inc's stock.
As per our most recent records Amedisys Inc has 19,000 Employees.
Amedisys Inc's registered address is 3854 American Way, Baton Rouge, LA, United States, 70816.
You can get more information about it from Amedisys Inc's website at https://www.amedisys.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Amedisys Inc (AMED) Stock
Based on ratings from 2 analysts Amedisys Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on AMED's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for AMED is USD 101.00 over the next 12 months. The maximum analyst target price is USD 101 while the minimum anlayst target price is USD 101.
AMED stock's Price/Earning ratio is 35.97.
Our analysis grades AMED stock's Price / Earning ratio at F. This means that AMED stock's Price/Earning ratio is above 56.00000000000001% of the stocks in the Medical Care Facilities sector in the NSD exchange.
Based on this AMED may be a overvalued for its sector.
The last closing price of AMED's stock was USD 90.64.
The most recent market capitalization for AMED is USD 2.97B.
Based on targets from 2 analysts, the average taret price for AMED is projected at USD 101.00 over the next 12 months.
This means that AMED's stock price may go up by +11.43% over the next 12 months.
We can't find any ETFs which contains Amedisys Inc's stock.
As per our most recent records Amedisys Inc has 19,000 Employees.
Amedisys Inc's registered address is 3854 American Way, Baton Rouge, LA, United States, 70816.
You can get more information about it from Amedisys Inc's website at https://www.amedisys.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AMED !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
